Company Analysis

Imunon, Inc. (IMNN)

Nasdaq: IMNN · Pharmaceutical Preparations · Lawrenceville, NJ · filing with the SEC since 1996
Grade4.1
◀ Past 4.4● Present 2.6▶ Future 5.3
2 est.

Who runs Imunon, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Lindborg Stacy
President and CEO. First filing Jun 2021, latest Nov 10, 2026, 1 filing in all.
Officers reporting now
8
of 12 people with a filing in the last fifteen months
Directors reporting now
4
22 people on the record since 2007
Officerssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Lindborg StacyPresident and CEOJun 2021Nov 10, 2026none
Tardugno Michael HExecutive Chairman of BoardJan 2007Nov 10, 2026none
Faller Douglas VincentChief Medical OfficerFeb 2025Nov 10, 2026none
Eylward SusanGeneral Counsel and Corp SecOct 2024Sep 1, 20266 · $0.00
Blacher JoshuaCFOJul 2026Jul 7, 2026none
Church Jeffrey WayneCFOJul 2010Jan 20, 2026none
Bragg KimberlyCFOJun 2025Jan 6, 2026none
Anwer KhursheedChief Scientific OfficerJun 2014Jan 6, 2026none
Directorssales are open-market, Nov 10, 2025 to Nov 10, 2026
NameRoleFirst filingLatest filingSales, 12 months
Braun Donald PdirectorDec 2015Nov 10, 2026none
Dentzer James EdirectorOct 2022Nov 10, 2026none
Fritz Frederick J.directorJul 2011Nov 10, 2026none
Pellizzari Christine AdirectorJun 2021Nov 10, 2026none
Earlier names on the record10, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton IMNN · research, not advice